Article Details

Triveni Bio: $115 Million (Series B) Closed To Advance Novel Antibody Treatments For I&I Disorders

Retrieved on: 2024-10-04 20:36:35

Tags for this article:

Click the tags to see associated articles and topics

Triveni Bio: $115 Million (Series B) Closed To Advance Novel Antibody Treatments For I&I Disorders. View article details on hiswai:

Excerpt

... Company and Deep Track Capital, and Series A investors Atlas Venture, Cormorant Asset Management, OrbiMed, Viking Global Investors, and Invus.

Article found on: pulse2.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up